

Supporting Information

Identification, characterization and molecular adaptation of class I redox systems for the production of multi-functionalized diterpenoids

Christian Görner^{a, ‡}, Patrick Schrepfer^{a, ‡}, Veronika Redai^a, Frank Wallrapp^b, Bernhard Loll^c, Wolfgang Eisenreich^e, Martin Haslbeck^f and Thomas Brück^{a, *}

^aDivision of Industrial Biocatalysis, Technical University of Munich, Lichtenberg Str. 4, 85748 Garching, Germany

^bChair of Bioinformatics, Technical University of Munich, Boltzmannstraße 3, 85748 Garching, Germany

^cInstitute for Chemistry and Biochemistry, Division of Structural Biology, Freie Universität Berlin, Takustr. 6, 14195 Berlin, Germany

^dChair of Biochemistry, Technical University of Munich, Lichtenberg Str. 4, 85748 Garching

^eChair of Biotechnology, Technical University of Munich, Lichtenbergstr. 4, 85748 Garching, Germany

‡These authors contributed equally.

* To whom correspondence should be addressed:

Thomas Brück

Fachgebiet für Industrielle Biokatalyse

Zentrum für Weiße Biotechnologie

Department für Chemie

Technische Universität München

Lichtenberg Str. 4, 85748 Garching, Germany

E-mail: brueck@tum.de

Content

1. <i>In vivo</i> assay	7
Figure S1a. <i>In vivo</i> assay for the conversion of cyclooctat-9-en-7-ol by CotB3 to cyclooctat-9-en-5,7-diol using different redox system variants. The data is illustrated as boxplot diagram (25 % to 75 % with whiskers with maximum 1.5 IQR) from five whole cell hydroxylation experiments. 100 % yield correspond to the median of the CotB3/AfR/Afx control	7
Figure S1b. <i>In vivo</i> assay for the conversion of cyclooctat-9-en-5,7-diol by CotB4 to cyclooctatin using different redox system variants. The data is illustrated as boxplot diagram (25 % to 75 % with whiskers with maximum 1.5 IQR) from five whole cell hydroxylation experiments. 100 % yield correspond to the median of the CotB3/AfR/Afx control	7
Figure S1c. SDS Page of the whole cell proteome from the <i>in vivo</i> assay (24 hours). The catalytic efficiency of CotB3 was evaluated using different redox system variants.	8
Table S1. Description of Figure S1c.....	8
Figure S1d. SDS Page of the whole cell proteome from the <i>in vivo</i> assay (24 hours). The catalytic efficiency of CotB4 was evaluated using different redox system variants.	9
Table S2. Description of Figure S1d	9
2. Bioinformatics	10
Figure S2a. Model of CotB3 harboring cyclooct-9-en-7-ol. Modelled CotB3 (gray), prosthetic heme group (magenta) and cyclooct-9-en-7-ol (blue).....	10
Figure S2b. Structural alignment of CotB3 (cyan) and P450cam (PDB-ID: 4JX1, red). The alignment has an RMSD of 0.142Å over 313 aligned residues with 19% sequence identity. Note that the RMSD value considers only atoms that are present in both structures. Not matching loops in CotB3 are not incorporated into the alignment. The interaction region of CotB3 with Afx/Pdx is part of the matched helical structures.	11
Figure S2c. Model of CotB4 harboring cyclooct-9-en-5,7-diol. Modelled CotB4 (gray), prosthetic heme group (magenta) and cyclooct-9-en-5,7-diol (blue).	12
Fig S2d. Structural alignment of CotB4 (cyan) and P450cam (PDB-ID: 4JX1, red). The alignment has an RMSD of 0.144Å over 339 aligned residues with 18% sequence identity. Note that the RMSD value considers only atoms that are present in both structures. Not matching loops in CotB4 are not incorporated into the alignment. The interaction region of CotB4 with Afx/Pdx is part of the matched helical structures.	13
Figure S2e. Modelled AfR•Afx complex with AfR harboring FAD (Flavin-Adenine-Dinucleotide) and Afx harboring inorganic Fe ₂ /S ₂ -cluster. AfR•Afx complex (dark blue/gray). AfR with bound prosthetic FAD (magenta) and Afx bound to inorganic Fe ₂ /S ₂ -cluster (light blue). W297 of AfR proposed to be acting in electron transfer is shown in red.....	14
Figure S2f. Modelled CotB3•Afx complex harboring cyclooct-9-en-7-ol. CotB3•Afx complex (dark blue/orange). CotB3 contains prosthetic heme group (magenta) and cyclooct-9-en-7-ol (light blue). Afx bound to inorganic Fe ₂ /S ₂ -cluster (green/magenta).....	15
Figure S2g. Modelled CotB4•Afx complex harboring cyclooct-9-en-7-ol. CotB4•Afx complex (dark blue/orange). CotB4 contains prosthetic heme group (magenta) and cyclooct-9-en-5,7-diol (light blue). Afx contains inorganic Fe ₂ /S ₂ -cluster (green/magenta).....	16

Figure S2h. Inner view of the Cotb3•Pdx complex (dark blue•red). Pdx contains inorganic Fe ₂ /S ₂ -cluster (green/magenta). CotB3 contains prosthetic heme group (gray) and cyclooct-9-en-7-ol (red). Essential hydrogen bonds for the interaction of Pdx and CotB3 to facilitate binding and electron transport are highlighted in black. Hydrogen bond formation between CotB3 _{R110} and CotB3 _{R114} with Pdx _{W106} needed for efficient binding and electron transfer, is strongly impaired due to the chemical nature of participating amino acids. The Cotb4•Pdx complex exhibits the same structure and also the same interacting residues.	17
Figure S2i. Inner view of the Cotb4•Afx complex (dark blue•red). Afx contains inorganic Fe ₂ /S ₂ -cluster (green/magenta). CotB4 contains prosthetic heme group (gray) and cyclooct-9-en-5,7-diol (red). Essential hydrogen bonds for the interaction of Afx and CotB4 to facilitate binding and electron transport are highlighted in black.	18
Figure S2j. Structural superposition of the PdR•Pdx (red•blue) with the modelled AfR•Afx complex (ocher•gray). Prosthetic FAD group of PdR and modelled AfR are shown in light blue. 2Fe-2S cluster of Pdx and modelled Afx are shown in magenta/green. The important hydrogen bridge (black) between Pdx _{D38} and PdR _{R310} needed for binding as well as PdR _{W330} facilitating electron transport are shown. Differing position of PdR _{W330} corresponding to W297 in AfR, presumably acting in electron transfer from FAD to Pdx is shown in ocher. Analogous interactions facilitating binding of AfR to Afx could not be deciphered. Substitution of Pdx _{D38} to E38 is suggested to impair electron transport by an alternate binding mode of Pdx _{D38E} to native PdR.	19
Figure S2k. Modelled CotB3 harboring (-)-casbene. CotB3 (light purple) contains prosthetic heme group (blue) and docked (-)-casbene (gray). The heme group contains the iron cation (magenta) and the dative bond to cysteine 408 (green) of the CotB3. (-)-Casbene is shown in the conformation comprising the lowest binding energy derived by cluster analysis of AutodockVina. Hydroxylated C-10 of (-)-casbene is shown in blue.....	20
Figure S2l. Modelled CotB3 harboring sinularcasbene D. CotB3 (light purple) contains prosthetic heme group (blue) and docked sinularcasbene D (gray). The heme group contains the iron cation (magenta) and the dative bond to cysteine 408 (green) of the CotB3. Sinularcasbene D is shown in the conformation comprising the lowest binding energy derived by cluster analysis of AutodockVina.....	21
Table S3. PROCHECK results of CotB3/4, AfR and Afx.	22
QMEAN Z-scores	22
Figure S2m. QMEAN Z-score of the AfR model (-0.31).....	22
Figure S2n. QMEAN Z-score of the Afx model (-0.10)	23
Figure S2o. QMEAN Z-score of the CotB3 model (-1.15).....	23
Figure S2p. QMEAN Z-score of the CotB4 model (-1.33).....	24
3. NMR-Spectroscopy	25
Figure S3a. ¹ H NMR (500 MHz, CDCl ₃) of cyclooctat-9-en-7-ol	25
Figure S3b. ¹³ C NMR (125 MHz, CDCl ₃) of cyclooctat-9-en-7-ol	26
Figure S3c. ¹ H NMR (500 MHz, CDCl ₃) of cyclooctat-9-en-5,7-diol.....	27
Figure S3d. ¹³ C NMR (125 MHz, CDCl ₃) of cyclooctat-9-en-5,7-diol	28
Figure S3e. ¹ H NMR (500 MHz, CD ₃ -OD) of cyclooctatin	29

Figure S3f. ^{13}C NMR (125 MHz, $\text{CD}_3\text{-OD}$) of cyclooctatin	30
Figure S3g. COSY (500 MHz, $\text{CD}_3\text{-OD}$) NMR of cyclooctatin	31
Figure S3h. HSQC (500 MHz, $\text{CD}_3\text{-OD}$) NMR of cyclooctatin.....	32
Figure S3i. NOESY NMR (500 MHz, $\text{CD}_3\text{-OD}$) of cyclooctatin	33
Figure S3j. ^1H NMR (500 MHz, CDCl_3) of the C-5 R-MTPA derivative of cyclooctat-9-en-5,7-diol. 34	
Figure S3k. ^{13}C NMR (125 MHz, CDCl_3) of the C-5 R-MTPA derivative of cyclooctat-9-en-5,7-diol	35
Figure S3l. COSY NMR (500 MHz, CDCl_3) of the C-5 R-MTPA derivative of cyclooctat-9-en-5,7-diol	36
Figure S3m. HSQC NMR (500 MHz, CDCl_3) of the C-5 R-MTPA derivative of cyclooctat-9-en-5,7-diol	37
Figure S3n. NOESY NMR (500 MHz, CDCl_3) of the C-5 R-MTPA derivative of cyclooctat-9-en-5,7-diol	38
Figure S3o. ^1H NMR (500 MHz, CDCl_3) of the C-5 S-MTPA derivative of cyclooctat-9-en-5,7-diol	39
Figure S3p. ^{13}C NMR (125 MHz, CDCl_3) of the C-5 S-MTPA derivative of cyclooctat-9-en-5,7-diol	40
Figure S3q. COSY NMR (500 MHz, CDCl_3) of the C-5 S-MTPA derivative of cyclooctat-9-en-5,7-diol	41
Figure S3r. HSQC NMR (500 MHz, CDCl_3) of the C-5 S-MTPA derivative of cyclooctat-9-en-5,7-diol	42
Figure S3s. NOESY NMR (500 MHz, CDCl_3) of the C-5 S-MTPA derivative of cyclooctat-9-en-5,7-diol	43
Chiral derivatizing and analysis.....	44
Figure S3t. ^1H NMR (500 MHz, CDCl_3) Overlay of the C-5 R/S-MTPA derivatives of cyclooctat-9-en-5,7-diol.....	44
Table S4. Experimental ^1H (CDCl_3 , 500 MHz, δ_{H}) and ^{13}C (CDCl_3 , 125 MHz, δ_{C}) NMR data of the C-5 R-MTPA derivatives of cyclooctat-9-en-5,7-diol	45
Table S5. Experimental ^1H (CDCl_3 , 500 MHz, δ_{H}) and ^{13}C (CDCl_3 , 125 MHz, δ_{C}) NMR data of the C-5 S-MTPA derivatives of cyclooctat-9-en-5,7-diol.....	46
Figure S4. $\Delta\delta$ (S – R) values (ppm) for the C-5 MTPA derivatives of cyclooctat-9-en-5,7-diol	47
Figure S5a. ^1H NMR (500 MHz, CDCl_3) of (-)-Casbene	48
Figure S5b. ^{13}C NMR (125 MHz, CDCl_3) of (-)-Casbene	49
Table S6. Experimental ^1H (CDCl_3 , 500 MHz, δ_{H} , J in Hz) and ^{13}C (CDCl_3 , 125 MHz, δ_{C}) NMR data of sinularcasbane D.....	50
Figure S6. COSY and HMBC correlations of sinularcasbane D.....	51
Figure S7. Illustrated NOESY correlations of sinularcasbane D. Modelling was done using molecular mechanics (MM2) calculations with ChemDraw Ultra Ver. 13.0 (CambridgeSoft).	51
Figure S8a. ^1H NMR (500 MHz, CDCl_3) of sinularcasbane D.....	52

	Figure S8b. ¹ H NMR (500 MHz, CDCl ₃) of sinularcasbane D	53
	Figure S8c. ¹³ C NMR (125 MHz, CDCl ₃) of sinularcasbane D	54
	Figure S8d. COSY NMR (500 MHz, CDCl ₃) of sinularcasbane D	55
	Figure S8e. HSQC NMR (500 MHz, CDCl ₃) of sinularcasbane D	56
	Figure S8f. HMBC NMR (500 MHz, CDCl ₃) of sinularcasbane D	57
	Figure S8g. NOESY NMR (500 MHz, CDCl ₃) of sinularcasbane D	58
4.	CD-Spectroscopy	59
	Figure S9. Circular dichroism spectroscopy of cyclooctat-9-en-7-ol (a), cyclooctat-9-en-5-7-diol (b), cyclooctatin (c)	59
5.	Mass spectrometry	60
	Figure S10a. Mass spectrum of silylated cyclooctat-9-en-7-ol (RT: 21:16), recorded on a Trace GC Ultra with DSQII (Thermo Scientific), m/z was analyzed from [50-650]. m/z C ₂₃ H ₄₂ OSi calculated. 362.30.	60
	Figure S10b. Mass spectrum of silylated cyclooctat-9-en-5,7-diol (RT: 22:94), recorded on a Trace GC Ultra with DSQII (Thermo Scientific), m/z was analyzed from [50-650]. m/z C ₂₆ H ₅₀ O ₂ Si ₂ calculated 450.33.	60
	Figure S10c. Mass spectrum of silylated cyclooctatin (RT: 24:40), recorded on a Trace GC Ultra with DSQII (Thermo Scientific), m/z was analyzed from [50-650]. m/z C ₂₈ H ₅₆ O ₃ Si ₃ calculated 524.35.	61
	Figure S10f. Mass spectrum of sinularcasbane D (RT: 21:89), recorded on a Trace GC Ultra with DSQII (Thermo Scientific), m/z was analyzed from [50-650]. m/z C ₂₀ H ₃₂ O calculated 288.24.	61
	Figure S11. High resolution electron spray ionization of cyclooctat-9-en-7-ol (a) m/z ([M-H ₂ O] ⁺ 272.2568 calculated C ₂₀ H ₃₂ 272.2504, cyclooctat-9-en-5-7-diol (b) m/z ([M-H ₂ O] ⁺ 272.2450 calculated C ₂₀ H ₃₂ O 288.2453, cyclooctatin (c) m/z ([M-H ₂ O] ⁺ 304.2415 calculated C ₂₀ H ₃₂ O ₂ 304.2402.	62
	Figure S12. GC-MS spectra from cell pellet extract of a 72h shake flask culture of (-)-casbene and hydroxylation to sinularcasbane D by CotB3 on a Trace GC Ultra with DSQII (Thermo Scientific).....	63
6.	Genes	64
	Figure S13. Gene of 1-deoxy-D-xylulose 5-phosphate synthase (<i>dxs</i>)	64
	Figure S14. Gene of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (<i>dxp</i>)	65
	Figure S15. Bi-cistronic operon of 2-C-methyl-D-erythriol 4-phosphate cytidyltransferase synthase (<i>ispD</i>) 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (<i>ispF</i>)	66
	Figure S16. Gene of Isopentenyl-diphosphate delta isomerase (<i>Idi</i>)	66
	Figure S17. Gene of <i>cotB2</i>	67
	Figure S18. Bi-cistronic <i>cotB3/cotB4</i> operon	68
	Figure S19. Bi-cistronic <i>afR/afx</i> operon	69
	Figure S20. Bi-cistronic <i>pdR/pdx</i> operon	70
	Figure S21. (-)-casbene synthase (<i>cs</i>) from <i>Jatropha curcas</i>	71

Figure S22. Taxadiene synthase (*txs*) from *Taxus brevifolia* 72

1. *In vivo* assay

Figure S1a. *In vivo* assay for the conversion of cyclooctat-9-en-7-ol by CotB3 to cyclooctat-9-en-5,7-diol using different redox system variants. The data is illustrated as boxplot diagram (25% to 75% with whiskers with maximum 1.5 IQR) from five whole cell hydroxylation experiments. 100% yield correspond to the median of the CotB3/AfR/Afx control.




Figure S1b. *In vivo* assay for the conversion of cyclooctat-9-en-5,7-diol by CotB4 to cyclooctatin using different redox system variants. The data is illustrated as boxplot diagram (25% to 75% with whiskers with maximum 1.5 IQR) from five whole cell hydroxylation experiments. 100% yield correspond to the median of the CotB3/AfR/Afx control.




Figure S1c. SDS-Page of the whole cell proteome from the *in vivo* assay (24 hours). The catalytic efficiency of CotB3 was evaluated using different redox system variants.




Table S1. Description of Figure S1c

Lane #	Lane Description	Protein Band #	Protein Identified
1	Marker	1	CotB3
2	pACYC-Duet-1 (<i>afR/afx</i> , cotB3)	2	Pdx
3	pACYC-Duet-1 (<i>pdR/pdx</i> , cotB3)		
4	pACYC-Duet-1 (<i>pdR/pdx</i> -D38E, cotB3)		
5	pACYC-Duet-1 (<i>pdR/pdx</i> -D38E, cotB3)		
6	pACYC-Duet-1 (<i>pdR/pdx</i> -D38E/W106E, cotB3)		
7	pACYC-Duet-1 (empty)		

Figure S1d. SDS-Page of the whole cell proteome from the *in vivo* assay (24 hours). The catalytic efficiency of CotB4 was evaluated using different redox system variants.




Table S2. Description of Figure S1d

Lane #	Lane Description	Protein Band #	Protein Identified
1	Marker	1	CotB4
2	pACYC-Duet-1 (<i>afR/afx</i> , cotB4)	2	Pdx
3	pACYC-Duet-1 (<i>pdR/pdx</i> , cotB4)		
4	pACYC-Duet-1 (<i>pdR/pdx-D38E</i> , cotB4)		
5	pACYC-Duet-1 (<i>pdR/pdx-D38E</i> , cotB4)		
6	pACYC-Duet-1 (<i>pdR/pdx-D38E/W106E</i> , cotB4)		
7	pACYC-Duet-1 (empty)		

2. Bioinformatics

Figure S2a. Model of CotB3 harboring cyclooct-9-en-7-ol. Modelled CotB3 (gray), prosthetic heme group (magenta) and cyclooct-9-en-7-ol (blue).




Figure S2b. Structural alignment of CotB3 (cyan) and P450cam (PDB-ID: 4JX1, red). The alignment has an RMSD of 0.142 Å over 313 aligned residues with 19% sequence identity. Note that the RMSD value considers only atoms that are present in both structures. Not matching loops in CotB3 are not incorporated into the alignment. The interaction region of CotB3 with Afx/Pdx is part of the matched helical structures.




Figure S2c. Model of CotB4 harboring cyclooct-9-en-5,7-diol. Modelled CotB4 (gray), prosthetic heme group (magenta) and cyclooct-9-en-5,7-diol (blue).




Fig S2d. Structural alignment of CotB4 (cyan) and P450cam (PDB-ID: 4JX1, red). The alignment has an RMSD of 0.144 Å over 339 aligned residues with 18% sequence identity. Note that the RMSD value considers only atoms that are present in both structures. Not matching loops in CotB4 are not incorporated into the alignment. The interaction region of CotB4 with Afx/Pdx is part of the matched helical structures.




Figure S2e. Modelled AfR•Afx complex with AfR harboring FAD (Flavin-Adenine-Dinucleotide) and Afx harboring inorganic Fe₂/S₂-cluster. AfR•Afx complex (dark blue/gray). AfR with bound prosthetic FAD (magenta) and Afx bound to inorganic Fe₂/S₂-cluster (light blue). W297 of AfR proposed to be acting in electron transfer is shown in red.




Figure S2f. Modelled CotB3•Afx complex harboring cyclooct-9-en-7-ol. CotB3•Afx complex (dark blue/orange). CotB3 contains prosthetic heme group (magenta) and cyclooct-9-en-7-ol (light blue). Afx bound to inorganic Fe₂/S₂-cluster (green/magenta).




Figure S2g. Modelled CotB4•Afx complex harboring cyclooct-9-en-7-ol. CotB4•Afx complex (dark blue/orange). CotB4 contains prosthetic heme group (magenta) and cyclooct-9-en-5,7-diol (light blue). Afx contains inorganic Fe₂/S₂-cluster (green/magenta).




Figure S2h. Inner view of the Cotb3•Pdx complex (dark blue•red). Pdx contains inorganic Fe₂/S₂-cluster (green/magenta). CotB3 contains prosthetic heme group (gray) and cyclooct-9-en-7-ol (red). Essential hydrogen bonds for the interaction of Pdx and CotB3 to facilitate binding and electron transport are highlighted in black. Hydrogen bond formation between CotB3_{R110} and CotB3_{R114} with Pdx_{W106} needed for efficient binding and electron transfer, is strongly impaired due to the chemical nature of participating amino acids. The Cotb4•Pdx complex exhibits the same structure and also the same interacting residues.




Figure S2i. Inner view of the Cotb4•Afx complex (dark blue•red). Afx contains inorganic Fe₂/S₂-cluster (green/magenta). CotB4 contains prosthetic heme group (gray) and cyclooct-9-en-5,7-diol (red). Essential hydrogen bonds for the interaction of Afx and CotB4 to facilitate binding and electron transport are highlighted in black.




Figure S2j. Structural superposition of the PdR•Pdx (red•blue) with the modelled AfR•Afx complex (ocher•gray). Prosthetic FAD group of PdR and modelled AfR are shown in light blue. 2Fe-2S cluster of Pdx and modelled Afx are shown in magenta/green. The important hydrogen bridge (black) between Pdx_{D38} and PdR_{R310} needed for binding as well as PdR_{W330} facilitating electron transport are shown. Differing position of PdR_{W330} corresponding to W297 in AfR, presumably acting in electron transfer from FAD to Pdx is shown in ocher. Analogous interactions facilitating binding of AfR to Afx could not be deciphered. Substitution of Pdx_{D38} to E38 is suggested to impair electron transport by an alternate binding mode of Pdx_{D38E} to native PdR.




Figure S2k. Modelled CotB3 harboring (-)-casbene. CotB3 (light purple) contains prosthetic heme group (blue) and docked (-)-casbene (gray). The heme group contains the iron cation (magenta) and the dative bond to cysteine 408 (green) of the CotB3. (-)-Casbene is shown in the conformation comprising the lowest binding energy derived by cluster analysis of AutodockVina. Hydroxylated C-10 of (-)-casbene is shown in blue.




Figure S21. Modelled CotB3 harboring sinularcasbane D. CotB3 (light purple) contains prosthetic heme group (blue) and docked sinularcasbane D (gray). The heme group contains the iron cation (magenta) and the dative bond to cysteine 408 (green) of the CotB3. Sinularcasbane D is shown in the conformation comprising the lowest binding energy derived by cluster analysis of AutodockVina.




Table S3. PROCHECK results of CotB3/4, AfR and Afx.

	Most favored regions in RAMACHANDRAN Plot [%]	G-factor/ dihedral angles [average score]	G-factor/Main-chain covalent forces [average score]
CotB3	92.5	-0.20	-0.29
CotB4	90.4	-0.27	-0.32
AfR	92.8	-0.01	-0.13
Afx	94.1	-0.02	-0.09

Our models exceed the demanded 90% of the RAMACHANDRAN Plot factoring, which indicates that these are excellent models. Also the G-factors are all above the -0.5 threshold indicating that no unusual folding patterns occur.

QMEAN Z-scores

Figure S2m. QMEAN Z-score of the AfR model (-0.31).




Figure S2n. QMEAN Z-score of the Afx model (-0.10).




Figure S2o. QMEAN Z-score of the CotB3 model (-1.15).





Figure S2p. QMEAN Z-score of the CotB4 model (-1.33).



The QMEAN Z-score of the aforementioned modeled proteins suggest that these models are of comparable quality to high resolution experimental structures. The reference structures are a non-redundant subset of the PDB sharing less than 30% sequence identity among each other and are solved at a resolution below than 2 Å.

The structural overlap of the PdR•Pdx and AfR•Afx complexes displayed high agreement and were therefore not subjected to further adjustments. In contrast, the hydroxylases CotB3/4 showed extended secondary structure motifs compared to the P450cam template. Both CotB3/4 display additional loop regions which are missing in P450cam. Consequently, the extra protein loops could not be aligned with the P450cam template (Figure S2b, d). Hence the extra loops will also complicate the quality assessments as *ab initio* loop modelling of unknown proteins are a typical source of error during modelling approaches. Therefore, we have excluded the extra loop regions in CotB3/4 in our PROCHECK and QMEAN Z-score quality assessments. As the excluded loops are neither in the vicinity of the active site, heme group or the ferredoxin interaction domain, an effect on identification of essential amino acid interactions can be excluded. In the absence of x-ray crystal structures, our modelling methodology provides the best insights into the essential protein interactions that drive the observed catalytic processes.

3. NMR-Spectroscopy

Figure S3a. ^1H NMR (500 MHz, CDCl_3) of cyclooctat-9-en-7-ol.




Figure S3b. ^{13}C NMR (125 MHz, CDCl_3) of cyclooctat-9-en-7-ol.




Figure S3c. ^1H NMR (500 MHz, CDCl_3) of cyclooctat-9-en-5,7-diol.




Figure S3d. ^{13}C NMR (125 MHz, CDCl_3) of cyclooctat-9-en-5,7-diol.




Figure S3e. ^1H NMR (500 MHz, $\text{CD}_3\text{-OD}$) of cyclooctatin.




Figure S3f. ^{13}C NMR (125 MHz, $\text{CD}_3\text{-OD}$) of cyclooctatin.




Figure S3g. COSY (500 MHz, CD₃-OD) NMR of cyclooctatin.




Figure S3h. HSQC (500 MHz, CD₃-OD) NMR of cyclooctatin.




Figure S3i. NOESY NMR (500 MHz, CD₃-OD) of cyclooctatin.




Figure S3j ^1H NMR (500 MHz, CDCl_3) of the C-5 R-MTPA derivative of cyclooctat-9-en-5,7-diol.




Figure S3k. ^{13}C NMR (125 MHz, CDCl_3) of the C-5 R-MTPA derivative of cyclooctat-9-en-5,7-diol.




Figure S31. COSY NMR (500 MHz, CDCl_3) of the C-5 R-MTPA derivative of cyclooctat-9-en-5,7-diol.




Figure S3m. HSQC NMR (500 MHz, CDCl₃) of the C-5 R-MTPA derivative of cyclooctat-9-en-5,7-diol.




Figure S3n. NOESY NMR (500 MHz, CDCl_3) of the C-5 R-MTPA derivative of cyclooctat-9-en-5,7-diol.




Figure S3o. ^1H NMR (500 MHz, CDCl_3) of the C-5 S-MTPA derivative of cyclooctat-9-en-5,7-diol.




Figure S3p. ^{13}C NMR (125 MHz, CDCl_3) of the C-5 S-MTPA derivative of cyclooctat-9-en-5,7-diol.




Figure S3q. COSY NMR (500 MHz, CDCl_3) of the C-5 S-MTPA derivative of cyclooctat-9-en-5,7-diol.




Figure S3r. HSQC NMR (500 MHz, CDCl_3) of the C-5 S-MTPA derivative of cyclooctat-9-en-5,7-diol.





Figure S3s. NOESY NMR (500 MHz, CDCl₃) of the C-5 S-MTPA derivative of cyclooctat-9-en-5,7-diol.



Chiral derivatizing and analysis

Figure S3t. ^1H NMR (500 MHz, CDCl_3) Overlay of the C-5 R/S-MTPA derivatives of cyclooctat-9-en-5,7-diol.






Table S4. Experimental ^1H (CDCl_3 , 500 MHz, δ_{H}) and ^{13}C (CDCl_3 , 125 MHz, δ_{C}) NMR data of the C-5 R-MTPA derivatives of cyclooctat-9-en-5,7-diol.




Position	δ_{C}	δ_{H}
1	43.82	1.04, 1.52
2	36.61	2.39
3	36.06	1.97
4	40.20	1.49, 1.78
5	82.58	5.43
6	56.45	2.24
7	75.51	
8	40.86	1.94, 2.64
9	118.25	5.24
10	153.63	
11	44.70	
12	45.58	1.38, 1.60
13	23.34	1.36, 1.51
14	53.91	2.27
15	29.09	1.26
16	17.42	0.77
17	22.28	0.95
18	15.05	0.84
19	26.31	1.14
20	24.92	1.19

Table S5. Experimental ^1H (CDCl_3 , 500 MHz, δ_H) and ^{13}C (CDCl_3 , 125 MHz, δ_C) NMR data of the C-5 S-MTPA derivatives of cyclooctat-9-en-5,7-diol.




Position	δ_C	δ_H
1	43.75	1.04, 1.55
2	36.82	2.48
3	36.35	2.35
4	40.66	1.56, 1.93
5	82.82	5.36
6	56.57	2.19
7	75.31	
8	40.79	1.83, 2.60
9	118.26	5.17
10	153.57	
11	44.7	
12	45.57	1.37, 1.60
13	23.35	1.35, 1.51
14	53.89	2.25
15	29.10	1.26
16	17.44	0.75
17	22.27	0.93
18	15.18	0.95
19	25.72	0.75
20	24.9	1.21

Figure S4. $\Delta\delta$ (S – R) values (ppm) for the C-5 MTPA derivatives of cyclooctat-9-en-5,7-diol.



¹³C-NMR $\Delta\delta$ (S – R) values (ppm)



¹H-NMR $\Delta\delta$ (S – R) values (ppm)

Figure S5a. ^1H NMR (500 MHz, CDCl_3) of (-)-Casbene.




Figure S5b. ^{13}C NMR (125 MHz, CDCl_3) of (-)-Casbene.





Table S6. Experimental ^1H (CDCl_3 , 500 MHz, δ_{H} , J in Hz) and ^{13}C (CDCl_3 , 125 MHz, δ_{C}) NMR data of sinularcasbane D.



Position	δ_{C}	δ_{H}
1	30.80 (CH)	0.65 ddd (10.5, 8.7, 1.7)
2	25.97 (CH)	1.21 t (8.5)
3	121.41 (CH)	4.84 d (8.3)
4	135.89 (C)	
5	39.57 (CH ₂)	2.19 (m) 2.06 (m)
6	25.09 (CH ₂)	2.19 (m) 2.05 (m)
7	127.09 (CH)	4.87 ddd (6.7, 4.4, 1.2)
8	130.95 (C)	
9	48.15 (CH ₂)	2.35 (m) 2.08 (m)
10	67.00 (CH)	4.52 ddd (10.7, 9.1, 3.2)
11	127.01 (CH)	4.98 dq (9.2, 1.4)
12	140.31 (C)	
13	39.70 (CH ₂)	2.24 (m) 1.81 (m)
14	24.03 (CH ₂)	1.68 (m) 1.13 (m)
15	20.16 (C)	
16	29.06 (CH ₃)	1.07 (s)
17	15.74 (CH ₃)	0.96 (s)
18	16.08 (CH ₃)	1.62 (s)
19	17.25 (CH ₃)	1.59 (s)
20	18.72 (CH ₃)	1.66 (s)

Figure S6. COSY and HMBC correlations of sinularcasbane D.




Figure S7. Illustrated NOESY correlations of sinularcasbane D. Modelling was done using molecular mechanics (MM2) calculations with ChemDraw Ultra Ver. 13.0 (CambridgeSoft).




Figure S8a. ^1H NMR (500 MHz, CDCl_3) of sinularcasbane D.




Figure S8b. ^1H NMR (500 MHz, CDCl_3) of sinularcasbane D.




Figure S8c. ^{13}C NMR (125 MHz, CDCl_3) of sinularcasbane D.




Figure S8d. COSY NMR (500 MHz, CDCl₃) of sinularcasbane D.




Figure S8e. HSQC NMR (500 MHz, CDCl₃) of sinularcasbane D.




Figure S8f. HMBC NMR (500 MHz, CDCl₃) of sinularcasbane D.






Figure S8g. NOESY NMR (500 MHz, CDCl₃) of sinularcasbane D.



4. CD-Spectroscopy

Figure S9. Circular dichroism spectroscopy of cyclooctat-9-en-7-ol (**a**), cyclooctat-9-en-5,7-diol (**b**), cyclooctatin (**c**).



5. Mass spectrometry

Figure S10a. Mass spectrum of silylated cyclooctat-9-en-7-ol (RT: 21:16), recorded on a Trace GC Ultra with DSQII (Thermo Scientific), m/z was analyzed from [50-650]. m/z $C_{23}H_{42}OSi$ calculated. 362.30.




Figure S10b. Mass spectrum of silylated cyclooctat-9-en-5,7-diol (RT: 22:94), recorded on a Trace GC Ultra with DSQII (Thermo Scientific), m/z was analyzed from [50-650]. m/z $C_{26}H_{50}O_2Si_2$ calculated 450.33.




Figure S10c. Mass spectrum of silylated cyclooctatin (RT: 24:40), recorded on a Trace GC Ultra with DSQII (Thermo Scientific), m/z was analyzed from [50-650]. m/z $C_{28}H_{56}O_3Si_3$ calculated 524.35.




Figure S10f. Mass spectrum of sinularcasbane D (RT: 21:89), recorded on a Trace GC Ultra with DSQII (Thermo Scientific), m/z was analyzed from [50-650]. m/z $C_{20}H_{32}O$ calculated 288.24.




Figure S11. High resolution electron spray ionization of cyclooctat-9-en-7-ol (a) m/z $[[M-H_2O]^+$ 272.2568 calculated $C_{20}H_{32}$ 272.2504, cyclooctat-9-en-5,7-diol (b) m/z $[[M-H_2O]^+$ 272.2450 calculated $C_{20}H_{32}O$ 288.2453, cyclooctatin (c) m/z $[[M-H_2O]^+$ 304.2415 calculated $C_{20}H_{32}O_2$ 304.2402.





Figure S12. GC-MS spectra of a 72h shake flask culture of (-)-casbene and hydroxylation to sinularcasbane D by CotB3 on a Trace GC Ultra with DSQII (Thermo Scientific). 20 % of (-)-casbene were hydroxylated to sinularcasbane D.



6. Genes

Figure S13. Gene of 1-deoxy-D-xylulose 5-phosphate synthase (dxs).

CCATGGATGAGTTTTGATATTGCCAAATACCCGACCCTGGCACTGGTTCGACTCCACCCAGGAGTT
ACGACTGTTGCCGAAAGAGAGTTTTACCGAAACTCTGCGACGAACTGCGCCGCTATTTACTCGACA
GCGTGAGCCGTTCCAGCGGGCACTTCGCCTCCGGGCTGGGCACGGTCGAACTGACCGTGGCGC
TGCACTATGTCTACAACACCCCGTTTTGACCAATTGATTTGGGATGTGGGGCATCAGGCTTATCCG
CATAAAATTTTGACCGGACGCCGCGACAAAATCGGCACCATCCGTCAGAAAGGCGGCCTGCACC
CGTTCCCGTGGCGCGGCGAAAGCGAATATGACGTATTAAGCGTCGGGCATTCATCAACCTCCAT
CAGTGCCGGAATTGGTATTGCGGTTGCTGCCGAGAAAGAAGGCAAAAATCGCCGCACCGTCTGT
GTCATTGGCGATGGCGCGATTACCGCTGGCATGGCGTTTGAAGCGATGAATCACGCGGGCGATA
TCCGTCCTGATATGCTGGTGGTCCTCAACGACAATGAAATGTCGATTTCCGAAAATGTCGGCGCG
CTCAATAACCATCTGGCACAGCTGCTTCCGGTAAGCTTTACTCTTCGCTGCGCGAAGGCGGGAA
AAAAGTTTTCTCTGGCGTTCCGCCAATTAAGAGCTGCTCAAACGTACCGAAGAACATATTAAGG
CATGGTAGTGCTGGCACGTTGTTTGAAGAGCTGGGCTTTAACTACATCGGCCCGGTTGACGGT
CACGATGTGCTGGGGCTTATCACCACGCTGAAGAACATGCGCGACCTGAAAGGCCCGCAGTTCC
TGCATATCATGACCAAAAAAGGTCGTGGTTATGAACCGGCAGAAAAAGACCCCATCACTTTCCAC
GCCGTGCCTAAATTTGATCCCTCAGCGGTTGTTTGCCGAAAAGTAGCGGCGGTTTGCCGAGCT
ATTCAAAATCTTTGGCGACTGGTTGTGCGAAACGGCAGCGAAAGACAACAAGCTGATGGCGATT
ACTCCGGCGATGCGTGAAGGTTCCGGCATGGTCGAGTTTTACGTAATTCCCGGATCGTTACTT
CGACGTGGCAATCGCCGAGCAACACGCGGTGACCTTTGCCGCCGGTCTGGCGATTGGTGGGTA
CAAACCCATTGTCGCGATTTACTCCACTTTCCTGCAACGCGCCTATGATCAGGTGCTGCATGACG
TGGCGATTCAAAGCTCCCGTCTGTTCCGCATCGACCGCGCGGGCATTGTTGGTGTGACGG
TCAAACCCATCAGGGCGCTTTTGACCTCTTTACCTGCGCTGTATACCGGAAATGGTCATTATGA
CCCCGAGCGATGAAAACGAATGTCGCCAGATGCTCTATACCGGCTATCACTATAACGACGGCCC
GTCCGCGGTGCGCTACCCGCGCGGTAACGCGGTTGGCGTGGAAGTACGCGCGCTGGAAAACT
GCCAATTGGCAAAGGCATTGTGAAGCGTCGTGGCGAGAACTGGCGATCCTTAACTTTGGTACG
CTGATGCCAGACGCGGCGAAAGTCGCTGAATCGCTGAACGCTACGCTGGTCGATATGCGTTTTG
TGAAACCGCTTGATGAAGCGTTAATTCTGGAAATGGCCGCCAGCCATGAAGCGCTGGTCACCGT
AGAAGAAAACGCCATTATGGGCGGCGCAGGCAGCGGCGTGAACGAAGTGCTAATGGCCCATCG
TAAACCAGTACCCGTGCTGAACATTGGCCTGCCTGACTTCTTTATTCCACAAGGAACTCAGGAAG
AAATGCGCGCCGAACTCGGCCTCGATGCCGCGGTATGGAAGCCAAAATCAAGGCCTGGCTGG
CATAAGAATTC

Figure S14. Gene of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (*dxp*).

CATATGAAGCAACTCACCATTCTGGGCTCGACCGGCTCGATTGGTTGCAGCACGCTGGACGTGG
TGCGCCATAATCCCGAACACTTCCGCGTAGTTGCGCTGGTGGCAGGCAAAAATGTCACTCGCAT
GGTAGAACAGTGCCTGGAATTCTCTCCCGCTATGCCGTAATGGACGATGAAGCGAGTGGAAA
CTTCTTAAAACGATGCTACAGCAACAGGGTAGCCGCACCGAAGTCTTAAGTGGGCAACAAGCCG
CTTGCGATATGGCAGCGCTTGAGGATGTTGATCAGGTGATGGCAGCCATTGTTGGCGCTGCTGG
GCTGTTACCTACGCTTGCTGCGATCCGCGCGGGTAAAACCATTTTGCTGGCCAATAAAGAATCAC
TGGTTACCTGCGGACGTCTGTTTATGGACGCCGTAAAGCAGAGCAAAGCGCAATTGTTACCGGT
CGATAGCGAACATAACGCCATTTTTCAGAGTTTACCGCAACCTATCCAGCATAATCTGGGATACG
CTGACCTTGAGCAAAATGGCGTGGTGTCCATTTTACTTACCGGGTCTGGTGGCCCTTTCCGTGAG
ACGCCATTGCGCGATTTGGCAACAATGACGCCGGATCAAGCCTGCCGTCATCCGAACTGGTCGA
TGGGGCGTAAAATTTCTGTCGATTCCGGCTACCATGATGAACAAAGGTCTGGAATACATTGAAGCG
CGTTGGCTGTTTAAACGCCAGCGCCAGCCAGATGGAAGTGTGATTACCCCGCAGTCAGTGATTC
ACTCAATGGTGCCTATCAGGACGGCAGTGTTCTGGCGCAGCTGGGGGAACCGGATATGCGTAC
GCCAATTGCCACACCATGGCATGGCCGAATCGCGTGAACCTCTGGCGTGAAGCCGCTCGATTTT
TGCAAATAAGTGCCTTGACATTTGCCGCACCGGATTATGATCGTTATCCATGCCTGAAACTGGC
GATGGAGGCGTTTGAACAAGGCCAGGCAGCGACGACAGCATTGAATGCCGCAAACGAAATCACC
GTTGCTGCTTTTCTTGCGCAACAAATCCGCTTTACGGATATCGCTGCGTTGAATTTATCCGTA
GAAAAATGGATATGCGCGAACCAACAATGTGTGGACGATGTGTTATCTGTTGATGCGAACGCGCG
TGAAGTCGCCAGAAAAGAGGTGATGCGTCTCGCAAGCTGACTCGAG

Figure S15. Bi-cistronic operon of 2-C-methyl-D-erythriol 4-phosphate cytidyltransferase synthase (*ispD*) 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (*ispF*).

CCATGGATGGCAACCACTCATTGGATGTTTGGCCGCGTGGTTCCGGCGGCCGGATTTGGCCGTC
GAATGCAAACGGAATGTCCTAAGCAATATCTCTCAATCGGTAATCAAACCATTCTTGAACACTCGG
TGCATGCGCTGCTGGCGCATCCCCGGGTGAAACGTGTCGTCATTGCCATAAGTCCTGGCGATAG
CCGTTTTGCACAACCTTCTCTGGCGAATCATCCGCAAATCACCGTTGTAGATGGCGGTGATGAGC
GTGCCGATTCCGTGCTGGCAGGTTTAAAGCCGCTGGCGACGCGCAGTGGGTATTGGTGCATG
ACGCCGCTCGTCCTTGTCTGCATCAGGATGACCTCGCGCGATTGTTGGCGTTGAGCGAAACCAG
CCGCACGGGAGGGATCCTAGCCGCACCAGTGCGCGATACGATGAAACGTGCCGAACCGGGCAA
AAATGCCATTGCTCATACCGTTGATCGCAACGGCTTATGGCACGCGCTGACGCCGCAATTTTTCC
CTCGTGAGCTGTTACATGACTGTCTGACGCGCGCTCTAAATGAAGGCGCGACTATTACCGACGAA
GCCTCGGCGCTGGAATATTGCGGATTCCATCCTCAGTTGGTTCGAAGGCCGTGCGGATAACATTA
AAGTCACGCGCCCGGAAGATTTGGCACTGGCCGAGTTTTACCTCACCCGAACCATCCATCAGGA
GAATACATAAGCAGGAGCAGGAGCAGAAGGAGGAGCAGGAATGCGAATTGGACACGGTTTTGAC
GTACATGCCTTTGGCGGTGAAGGCCCAATTATCATTGGTGGCGTACGCATTCTTACGAAAAAGG
ATTGCTGGCGCATTCTGATGGCGACGTGGCGCTCCATGCGTTGACCGATGCATTGCTTGGCGCG
GCGGCGCTGGGGGATATCGGCAAGCTGTTCCCGGATACCGATCCGGCATTAAAGGTGCCGAC
AGCCGCGAGCTGCTACGCGAAGCCTGGCGTCGTATTACGGCGAAGGGTTATACCCTGGGCAAC
GTCGATGTCATCATCGCTCAGGCACCGAAGATGTTGCCGCACATTCCACAAATGCGCGTATT
TATTGCCGAAGATCTCGGCTGCCATATGGATGATGTTAACGTGAAAGCCACTACTACGGAAAAAC
TTGGATTTACCGGACGTGGGGAAGGGATTGCCTGTGAAGCGGTGGCGCTACTCATTAAAGGCAAC
AAAATGAGAATTC

Figure S16. Gene of Isopentenyl-diphosphate delta isomerase (*idi*).

CATATGCAAACGGAACACGTCATTTTTATTGAATGCACAGGGAGTTCCACGGGTACGCTGGAAAA
GTATGCCGCACACACGGCAGACACCCGCTTACATCTCGCGTTCTCCAGTTGGCTGTTTAAATGCCA
AAGGACAATTATTAGTTACCCGCCGCGCACTGAGCAAAAAAGCATGGCCTGGCGTGTGGACTAA
CTCGGTTTTGTGGGCACCCACAACCTGGGAGAAAGCAACGAAGACGCAGTATCCGCCGTTGCCGT
TATGAGCTTGGCGTGGAAATTACGCCTCCTGAATCTATCTATCCTGACTTTTCGCTACCGCGCCAC
CGATCCGAGTGGCATTGTGAAAAATGAAGTGTGTCCGGTATTTGCCGCACGCACCACTAGTGCG
TTACAGATCAATGATGATGAAGTGTGGATTATCAATGGTGTGATTTAGCAGATGTATTACCGGT
ATTGATGCCACGCCGTGGGCGTTTCAGTCCGTGGATGGTGTGATGCAGGCGACAAATCGCGAAGCCA
GAAAACGATTATCTGCATTTACCCAGCTTAAATAACTCGAG

Figure S17. Gene of *cotB2*.

CATATGACCACCGGTCTGAGCACCGCAGGCGCACAGGATATTGGTCGTAGCAGCGTTTCGT
CCGTATCTGGAAGAATGTACCCGTCGTTTTCAAGAAATGTTTGATCGTCATGTTGTTACC
CGTCCGACCAAAGTTGAACTGACCGATGCAGAACTGCGTGAAGTTATTGATGATTGTAAT
GCAGCAGTTGCACCGCTGGGTAAAACCGTTAGTGATGAACGTTGGATTAGCTATGTTGGT
GTTGTTCTGTGGTACACAGAGTCCGCGTCATATTAAGATATGGAAGCATTAAAGCCGTG
TTCGTTCTGAATTGTGTTACCTTTGTTGGGATGATATGGACCCTGCACTGCATGATTTT
GGTCTGTTTCTGCCTCAGCTGCGTAAAATTTGCGAAAAATACTATGGTCCGGAAGATGCC
GAAGTTGCCTATGAAGCAGCACGTGCATTTGTTACCAGCGATCACATGTTTCGTGATAGC
CCGATTAAGCAGCACTGTGTACCACCAGTCCGGAACAGTATTTTCGTTTTCGTGTTACC
GATATTGGCGTGGATTTTTGGATGAAAATGAGCTATCCGATTTATCGCCATCCGGAATTT
ACCGAACATGCAAAAACCGCCTGGCAGCACGTATGACCACCCGTGGTCTGACCATTGTT
AATGATTTCTATAGCTATGATCGCGAAGTTAGCCTGGGTCAGATTACCAATTGTTTTCGT
CTGTGTGATGTGAGTGATGAAACCGCCTTTAAAGAATTTTTTCAGGCACGTCTGGATGAC
ATGATCGAAGATATTGAATGCATCAAAGCGTTTGATCAGCTGACACAGGATGTTTTTCTG
GATCTGATTTATGGCAATTTTGTGTGGACCACCTCCAACAAACGTTATAAAACCGCAGTG
AATGATGTGAACAGCCGTATTCAATAACTCGAG

Figure S18. Bi-cistronic *cotB3/cotB4* operon.

CATATGCGTGAACGTGGTCCGGTTACACCGGCAAAAAGCAGCGCACCGCCTGAACGTCCG
TGGACCACCGGTACAGCACCGGGTAGCGTTCGGCTGCTGGGTCATACAATGGCACTGTGG
CGTCGTCCGCTGCAATTTCTGGCAAGCCTGCCTGCACATGGTGATCTGGTTGAAGTTCGT
CTGGGTCCGAGCCGTGCATATCTGGCATGTCATCCGGAACCTGGTTCGTCAGGTTCTGCTG
AATCCGCGTGTTTTGATAAAGGTGGCGTTTTCGATAAAGCACGTCAGCTGCTGGGCAAT
AGCCTGAGCGTTAGCCGTGGTGAAGATCATCGTTATCAGCGTCGTATGATTCAGCCTGCA
TTTTATACCCCGAAAATTGCCGCATATACCGCAGCAGTTGCAGATGATACCCGTGCAGCA
ATTGGTAGCTGGGAACCGGGTCGTACCCTGGATATTAGCGATAACCATGCATGCACTGCTG
ATGCGTGTTGCAGCAGCTACCCTGTTTAGCACCGGTATTGATGAAGCAACCATCGATGAA
GCCCCGTCATTGTCTGCGTATTGTTAGTGATGGTATCTATAAACGTACGATGGCACCGCTG
GGTATTATGAAAAACTGCCGACACCGGGTAATCGTCGTTATGATCGTGCAAATGCACGT
CTGCGTCAGATTGTTGATGAAATGATTTCGTGAACGTCGTCGTAGCGGTGCAGATCATGGC
GATCTGCTGAGCACCTGCTGCGTGCAGAACATCCGGAAACCGGTAAAGGTCTGGATGAT
GGTGAAGTTCGGATCAGGTTGTTACCTTTCTGGTTGCAGGTAGCGAAACCACCGCAAGC
ACCCTGGCATTGTTTTTCATCTGCTGGGTGCCCATCCGGAAGTTGAAAAACGTGTTTCAT
GCAGAAATCGATGAAATTCTGGAAGGTGCTAGCCCGACCTTTGAAGATCTGCCGAGCCTG
GAATATACCCGTGGTGTTATTACCGAAAGCCTGCGTCTGTATCCGCCTAGCTGGATGGCA
ATGCGTGTTACCGCAGCCGAAACCGAACTGGGTGGTTCGTACCCTCCGGCAGGCACCATG
ATTCTGTATAGCGCACAGGCACTGCATCATAACCCGGAACCTGTTTCCAGATCCGGAACGT
TTTGATCCTGAACGTTGGCTGGGTGATCGTGCCAAAGAAGTTGAACGCGGAGCACTGCTG
CCGTTTGGTGCCGGTAGCCATAAATGTATTGGTGATGTGCTGGCACTGACCGAAACAGCA
CTGATTGTTGCAACCATTGCAAGCCGTTGGCGTCTGCGTCCGGTCCGGGTACAACCCTG
CGTCTGAACCGAAAAGCAACCCTGGAACCTGGTCCGCTGCCGATGGTTTGTGAACCGCGT
TAACTAGTAGGAGGAAAACATCATGAAAGATTTTTTCGTATGCGCACCGCACAGCAGCC
TGCCACACGTCATTGGCGTCATACCGTTGCACCGGGTGGTCTGCCGCTGGCAGGTCACGC
TCTGCTGATGGCACGTAAACCTCTGCAATTCCTGGCCTCACTGCCAGCCCACGGCGATCT
GGTGGAACCTGCGCCTGGGACCGCGTCCGGTGTATCTGCCGTGCCACCCTGAACTGGTGCA
GCAGGTAAGTAAATGCACGTGTTTATGATACAGGCGGTCCGGTGAAGAAAAAGCAAA
ACCGATTCTGGTAATGGTCTGATTACCAGCGATTGGGCTGATCATCGTCGCCAGCGTCG
CCTGTTTACGCCAGCCTTTACACCCGCAGTATTGCAAAGTATGCCGAAGTTATGGAACG
TGAATGTGAAGCAGAAAGCACCGCATGGACCGCACGTCGTCGATTGATGTTAGCCATGA
AATGCTGGCCCTGACAGCACGCGTTACCGCACGTCGACTGTTTTCAACCGATATGGCTCC
GCATGCCGTTGCAGAAATTCAGCATTGCCTGCCGATTGTTGTTGAAGGTGCATATCGTCA
GGCAATTGATCCGACCGGTCTGCTGGCCAAACTGCCTCTGGCAGCAAATCGTCGCTTTGA
TGATGCACTGGCACGTCTGAACCAGCTGATTGATCGCATGATTGATGATTACAAAGCCAG
TGATGATGGCGATCGTGGTGATGTTCTGAGCGCACTGTTTGCAGCACAGGATGATGAAAC
CGGTGGTACAATGAGCGATCAAGAAATTCATGATCAGGTTATGACACTGCTGCTGGCTGG
TATTGAAACCACAGCCAGCGCACTGACCTGGGCATGGTTTCTGCTGGGACGTAATCCGGG
TGCGGAAGCAGCACTGCATGCGGAAGTGGATGAAGTGTGCTGGGTGGCCGTGCACCGCGTTA
TGCAGATGTTCCGCGTCTGGCATATACACAGCGTGTGTTTAGCGAAGCCCTGCGCCTGTT
TCCTCCGGCATGGCTGTTTACCCGTACCACCACCGAAACCACGGAACCTGGGAGGCCGTCG
TCTGCCTCCGGCTTCAGATGTGCTGATTAGCCCGTATGTGCTGCATCGTATCCAGCACT
GTTTCCGCGTCTGATAGCTTTGACCCGGATCGTTGGCTGCCAGAACCGCGCAAAAAGAAGT
AACACGCGGTAGCTATCTGCCTTTTGGTGGTGGTTCACGTAATGCATTGGCGACGTTTT
TGGTATGACCGAAGCAAACTGGCACTGGCAGCGATTGCCGGTCTGTTGGCGGATGCGTCC
TATTCTGGCACCAAAATTCGTCCGCGTCCGCAGATGAGCCTGACCGCAGGTCTCTGCG
CATGATTCCGGAACCTCGTTAACTCGAG

Figure S19. Bi-cistronic *afR/afx* operon.

CCATGGGCCCTGCAAATGATGCCTGTGTTATTGTTGGTGCAGGTCTGGCAGGCGCAAAG
CAGCACAGGCACTGCGTGAAGAGGGTTTTGATGGTCCGCTGGTTCTGATTGGTGAAC
GTGAACGTCCGTATGAACGTCCTCCGCTGAGCAAAGGTTATCTGACCGGTAAAGATGCAC
GTGAGCAGATTTATGTTTCATCCGCCTCAGTGGTATGCAGAACATAATGTTGATATGCGTC
TGGGTATGGCAGTTACCGCAGTTGATCCGGCAGCACGTGAAATGACCCTGGATGATGGTA
GCCGTGTTGGTTATGGTAAACTGCTGCTGACCACCGGTAGCGCACCGCGTCGTCTGCCGG
TTCCTGGTGCTGGCCTGGAACGTGTTCTGTATCTGCGTCGTGTTGAAGATAGCGATCAGA
TTAAAGAAGCATTTCAGAGCGCAAGCCGTGCAGTTGTTATTGGTGCCGGTTGGATTGGTC
TGAAACCACCGCAGCAGCACGTACCGCAGGCGTTGAAGTTACCGTTCTGGAAATGGCAG
AACTGCCGCTGCTGCGTGTCTGGGTGCTGAAGTTGCACAGCTGTTTGCAAATCTGCATC
GTGATCATGGTGTGATCTGCGTTTTGGTGCACAGGTTGCAGAAATTACCGGTAGTGGTG
GTGCAGTTGATGGTGTTCGTCTGAGTGATGGCACCCGTATTGATGCAGATGTTGTGATTG
TGGGTGTTGGCATTAAACCGAATATTGGCCTGGCACAAGAAGCCGGTCTGGAAGTTGATA
ATGGTATTCGTGTGGATGAACGTCTGCGTACCAGCTATCCTGATATTTATGCAGCCGGTG
ATGTTGCACATGCATTTTCATCCGCTGCTGGGTAAACATATTCGCGTTGAACATTGGGCAA
ATGCACTGAATCAGCCGCAGATTGCAGCAAAGCAATGCTGGGTCCGGAAGATGCCGTTT
ATGATCGTATTCCGTATTTTTTACCAGATCAGTATGATCTGGGCATGGAATATGCAGGTT
ATGTTGAACCGGGTGGTTATGATCAGGTTGTTTTTCTGGTGATGTGGCAGGTCGTGAAT
TTATTGCATTTTGGCTGGCAGGCAATCGTGTGCTGGCAGGTATGAATGTGAATATTTGGG
ATGTTAATGATCAGCTGCAGACCCTGGTTCGTACCGCACAGACCGTTGATATTCCGATGC
TGACCGATCCGCAGGTTCCGCTGGGTAGCCTGCTGCCTGATCCTCAGCATCGTTAATATA
TTAGTTAAGTATAAGAAGGAGATATAATGCCGAAAGTTACCTATGTTAGTGATGCCGGTG
AAGTTCGTGTTGTTGATGGTCTGGTTGGTGATAGCGTTATGCAGACCGCAGTTCGTAATG
GTGTTCCGGGTATTACCGGTGAATGTGGTGGTGTCTGAGCTGTGCAACCTGTCATGTTT
TTGTTGATGAAGCAGATCTGGATCGTCTGGAACCGGTTAGCGGTCTGGAAGATGAAATGC
TGGATGGCACCGTTGTTGATCGTTGTCCGAATAGCCGTCTGAGCTGCCAGATTAAACTGA
GCGAAGAACTGGGTGATCTGCGTGTACCACACCGGAAGCACAAAGAATAAGCGGCCGC

Figure S20. Bi-cistronic *pdR/pdx* operon.

CCATGGGCAACGCCAATGATAATGTTGTTATTGTTGGCACCGGTCTGGCAGGCGTTGAAGTTGCA
TTTGGTCTGCGTGCAAGCGGTTGGGAAGGTAATATTCGTCTGGTTGGTGATGCAACCGTTATTCC
GCATCATCTGCCTCCGCTGAGCAAAGCATATCTGGCAGGTAAAGCAACCGCAGAAAGCCTGTAT
CTGCGTACACCGGATGCCTATGCAGCACAGAATATTCAGCTGCTGGGTGGTACACAGGTTACCG
CAATTAATCGTGATCGTCAGCAGGTTATTCTGAGTGATGGTCGTGCACTGGATTATGATCGTCTG
GTGCTGGCAACCGGTGGTCGTCCGCGTCCGCTGCCGTTGCAAGTGGTGCAGTTGGTAAAGCC
AATAACTTTTCGTTATCTGCGCACCCCTGGAAGATGCAGAATGTATTCGTCTGTCAGCTGATTGCAGAT
AATCGCCTGGTTGTGATTGGTGGTGGTTATATTGGTCTGGAAGTTGCAGCAACCGCCATTAAGC
AAATATGCATGTTACCCTGCTGGATACCGCAGCACGTGTTCTGGAACGTGTTACCGCACCGCCTG
TTAGCGCCTTTTATGAACATCTGCATCGTGAAGCCGGTGTGATATTCGTACCGGCACCCAGGTT
TGTGGTTTTGAAATGAGCACCGATCAGCAGAAAGTTACCGCAGTTCTGTGTGAAGATGGCACCCG
TCTGCCTGCAGATCTGGTTATTGCAGGTATTGGCCTGATTCCGAATTGTGAAGTGGCAAGCGCAG
CAGGTCTGCAGGTTGATAATGGTATTGTTATTAACGAACACATGCAGACCAGCGATCCGCTGATT
ATGGCAGTTGGTGATTGTGCACGTTTTTCATAGCCAGCTGTATGATCGTTGGGTTTCGTATTGAAAG
CGTTCCGAATGCACTGGAACAGGCACGTAAAATTGCAGCAATTCTGTGTGGTAAAGTTCCGCGTG
ATGAAGCAGCACCGTGGTTTTGGAGCGATCAGTATGAAATTGGTCTGAAAATGGTTGGTCTGAGC
GAAGGTTATGATCGCATTATTGTTTCGTGGTAGCCTGGCACAGCCGGATTTTTTCAGTTTTTTATCTG
CAGGGTGATCGTGTGCTGGCAGTTGATACCGTTAATCGTCCGGTTGAATTTAACCCAGAGCAAACA
AATTATCACCGATCGTCTGCCGGTGGAAACCGAATCTGCTGGGAGATGAAAGCGTGCCGCTGAAA
GAAATTATTGCAGCAGCAAAGCAGAACTGAGCAGCGCATAATATATTAGTTAAGTATAAGAAGGA
GATATAATGAGCAAAGTTGTGTATGTTAGCCATGATGGCACCCGTCGTGAAGTGGATGTTGCAGA
TGGTGTGAGCCTGATGCAGGCAGCAGTTAGCAATGGTATTTATGATATTGTTGGTATTGTGGTG
GTAGCGCAAGCTGTGCAACCTGTCATGTTTATGTTAATGAAGCCTTCACCGATAAAGTTCCGGCA
GCAAATGAACGTGAAATTGGTATGCTGGAATGTGTTACCGCAGAACTGAAACCGAATAGCCGCTCT
GTGTTGTCAGATTATTATGACACCGGAACTGGACGGTATTGTTGTTGATGTTCCGGATCGTCAGT
GGTAAGCGGCCGC

Figure S21.(-)-casbene synthase (*cs*) from *Jatropha curcas*.

CATATGGCAAGCACCAAAAGCGAAACCGAAGCACGTCCGCTGGCATATTTCCGCCTACCGTTTG
GGGTGATCGTCTGGCAAGCCTGACCTTTAATCAGCCTGCATTTGAACTGCTGAGTAAACAGGTTG
AGCTGCTGAACGAGAAAATCAAAAAAGAAATGCTGAATGTGAGCACCAGCGATCTGGCAGAAAA
ATCATTCTGATTGATAGCCTGTGTCGTCTGGGTGTTAGCTATCATTTTGAAGAAGAAATCCAAGAA
AACCTGACCCGCATCTTTAATACCCAGCCGAATTTTCTGAACGAAAAAGATTATGATTTATTCACC
GTGGCCGTGATCTTTCGTGTTTTTCGTCAGCATGGCTTTAAAATCAGCAGCGACGTTTTTAACAAA
TTCAAAGATAGCGACGGGAAATTCAAAGAAAGCCTGCTGAATGATATTAAGGCATCCTGAGCCT
GTTTGAAGCAACCCATGTTAGCATGCCGAATGAACCGATTCTGGATGAAGCACTGGCATTACCA
AAGCATTTCTGGAAAGCAGCGCAGTTAAATCCTTTCCGAATTTTGCCAAACATATTAGCAGCGCAC
TGGAACAGCCGGTTCATAAAGGTATTCCGCGTCTGGAAGCACGCAAATATATCGATCTGTATGAA
GTTGATGAAAGCCGCAATGAAACCGTGCTGGAAGTGGCGAAACTGGATTTTAATCGTGTTAGCT
GCTGCATCAAGAAGAACTGAGCCAGTTTAGCAAATGGTGGAAAAGCCTGAATATTAGTGCCGAAG
TTCCGTATGCACGTAATCGTATGGCAGAAATCTTTTTTTGGGCAGTGAGCATGTATTTTGAACCGC
AGTATGCAAAAGCCCGTATGATTGTTAGCAAAGTGGTTCTGCTGATTAGCCTGATTGATGATACCA
TTGATGCCTATGCCACCATCGATGAAATCCATCGTGTTGCAGATGCAATTGAACGTTGGGATATG
CGTCTGGTTGATCAGCTGCCGAATTATATGAAAGTGATTTATCGCCTGATCATCAACACCTTTGAT
GAGTTTAAAAAGATCTGGAAGCCGAGGGTAAAAGCTATAGCGTTAAATATGGTCGTGAAGCCTA
TCAAGAAGTGGTGCGTGGTTATTACCTGGAAGCAATTTGGAAAGCGGATGGTAAAGTTCCGAGCT
TCGATGAGTATATCTATAATGGTGGTGTACCACCGGTCTGCCGCTGGTTGCCACCGTTAGCTTT
ATGGGTGTTAAAGAAATCAAAGGCACCAAAGCCTTTCAGTGGCTGAAAACCTATCCGAAACTGAA
TCAGGCAGGCGGTGAATTTATTCGTCTGGTTAATGATGTTATGAGCCATGAAACCGAACAGGATC
GTGGTCATGTTGCAAGCTGTATTGATTGCTATATGAAACAGTATGGCGTGAGCAAAGAAGAAGCC
GTTGAAGAGATCCAGAAAATGGCAACCAATGAGTGGAAAAAACTGAACGAACAGCTGATTGTTCCG
TAGCACCGAAGTTGTTCCGGTTAATCTGCTGATGCGTATTGTTAATCTGGTTCGTCTGACCGATGT
GAGCTATAAATACGGTGATGGTTATACCGATAGCTCCCAGCTGAAAGAATATGTGAAAGGCCTGT
TTATTGAACCGATCGCAACCGGTACCTCTTAACTCGAG

Figure S22. Taxadiene synthase (*txs*) from *Taxus brevifolia*.

CATATGGCAATGAGCAGCAGCACCGGCACCAGCAAAGTTGTTAGCGAAACCAGCAGTACCATTG
TTGATGATATTCCGCGTCTGAGCGCAAATTATCATGGTGATCTGTGGCATCATAATGTGATTGAGA
CCCTGGAAACCCCGTTTTCTGAAAGCAGCACCTATCAAGAACGTGCAGATGAACTGGTTGTGAAA
ATCAAAGATATGTTAACGCACTGGGTGATGGTGATATTAGCCCGAGCGCCTATGATACCGCATG
GGTTGCACGTCTGGCAACCATTAGCAGTGATGGTAGCGAAAAACCGGTTTTCCGCAGGCACTG
AATTGGGTTTTTAAACAATCAGCTGCAGGATGGTAGTTGGGGTATTGAAAGCCATTTTAGCCTGTGT
GATCGTCTGCTGAATACCACCAATAGCGTTATTGCACTGAGCGTTTGGAAAACCGGTCATAGCCA
GGTTCAGCAGGGTGCAGAAATTTATTGCAGAAAATCTGCGCCTGCTGAATGAAGAAGATGAGCTGA
GTCCGGATTTTCAGATTATCTTTCCGGCACTGCTGCAGAAAAGCAAAGCACTGGGTATTAATCTG
CCGTATGATCTGCCGTTTATCAAATATCTGAGCACCAACCGTGAAGCACGTCTGACCGATGTTAG
CGCAGCAGCAGATAATATCCGGCAAATATGCTGAATGCACTGGAAGGTCTGGAAGAAGTTATTG
ACTGGAACAAAATTATGCGCTTCCAGAGCAAAGATGGTAGCTTTCTGAGTAGTCCGGCAAGCACC
GCATGTGTTCTGATGAATACCGGTGATGAAAAATGCTTTACCTTCTGAATAACCTGCTGGATAAA
TTTGGTGGTTGTGTTCCGTGTATGTATAGCATTGATCTGCTGGAACGTCTGAGCCTGGTTGATAAT
ATTGAACATCTGGGTATTGGTCCGCACTTCAAACAAGAAATTAAGGTGCACTGGATTACGTGTAT
CGTCATTGGAGCGAACGTGGTATTGGTTGGGGTTCGTGATAGCCTGGTTCCGGATCTGAATACAA
CCGCACTGGGCCTGCGTACCCTGCGTATGCATGGTTATAATGTTAGCTCAGATGTGCTGAACAAC
TTTAAAGATGAAAACGGTCGCTTTTTTAGCAGCGCAGGTCAGACCCATGTTGAACTGCGTAGCGT
TGTTAACCTGTTTCGTGCAAGCGATCTGGCATTTCGGATGAACGTGCAATGGATGATGCACGTA
AATTTGCAGAACCGTATCTGCGTGAAGCCCTGGCCACCAAATAGCACCAATACAAAATGTTTA
AAGAAATCGAATATGTGGTCGAGTATCCGTGGCACATGAGCATTCTCGTCTGGAAGCACGTAGC
TATATTGATAGCTATGATGATAACTATGTGTGGCAGCGTAAAACCTGTATCGTATGCCGAGCCTG
AGCAATAGCAAATGTCTGGAACCTGGCAAACCTGGATTTAACATTGTTTCAGAGCCTGCACCAAGA
AGAACTGAAACTGCTGACCCGTTGGTGGAAAGAAAGCGGTATGGCAGATATTAACCTTTACCCGTC
ATCGTGTGCCGAAGTGTATTTTAGCAGTGCAACCTTTGAACCGGAATATAGCGCAACCCGTATT
GCCTTTACCAAATTTGGTTGTCTGCAGGTCCTGTTTCGATGATATGGCCGATATTTTTGCAACCCTG
GATGAACTGAAAAGTTTTACCGAAGGTGTTAAACGTTGGGATACCAGTCTGCTGCATGAAATCCC
GGAATGTATGCAGACCTGTTTTAAAGTGTGGTTTTAACTGATGGAAGAGGTGAATAACGATGTGG
TTAAAGTTCAGGGTCGCGATATGCTGGCCCATATTCGTAACCGTGGGAACCTGATTTCAACTGC
TATGTTCAAGAACGCGAATGGCTGGAAGCCGGTTATATCCGACCTTTGAAGAATATCTGAAAAC
CTATGCAATTAGCGTTGGTCTGGGTCCGTGTACCCTGCAGCCGATTCTGCTGATGGGTGAACTG
GTGAAAGATGATGTTGTTGAGAAAGTTCATTACCCGAGCAACATGTTTGAACCTGGTAAGCCTGAG
CTGGCGTCTGACCAATGATACCAAACCTATCAGGCAGAAAAAGCACGTGGTCAGCAGGCAAGC
GGTATTGCATGTTATATGAAAGACAATCCGGGTGCAACCGAAGAGGATGCAATCAAACATATTTG
TCGTGTTGTTGATCGTGCCTGAAAGAAGCCAGCTTTGAATATTTCAAACCGAGCAACGATATTC
GATGGGCTGTAAATCCTTTATCTTTAATCTGCGTCTGTGCGTGCAGATCTTCTATAAATTCATTGAT
GGTTACGGCATTGCCAACGAAGAGATCAAAGATTATATCCGCAAAGTGTATATCGATCCGATTCA
GGTTAACTCGAG